Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells

Jamie L. Shirley; Geoffrey D. Keeler; Alexandra Sherman; Irene Zolotukhin; David M. Markusic; Brad E. Hoffman; Laurence M. Morel; Mark A. Wallet; Cox Terhorst; Roland W. Herzog

doi:10.1016/j.ymthe.2019.11.011

Type I IFN Sensing by cDCs and CD4⁺ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8⁺ T Cells

Jamie L. Shirley
, Geoffrey D. Keeler
, Alexandra Sherman
, Irene Zolotukhin
, David M. Markusic
, Brad E. Hoffman
, Laurence M. Morel
, Mark A. Wallet
, Cox Terhorst
, Roland W. Herzog

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

Immune responses complicate the use of adeno-associated virus (AAV) vectors in human gene therapy. Shirley et al. define a mechanism by which cross-presentation of viral capsid results in activation of CD8⁺ T cells, which involves sensing of IFN I by conventional dendritic cells and co-stimulation by CD4⁺ T helper cells.

Original language	English (US)
Pages (from-to)	758-770
Number of pages	13
Journal	Molecular Therapy
Volume	28
Issue number	3
DOIs	https://doi.org/10.1016/j.ymthe.2019.11.011
State	Published - Mar 4 2020
Externally published	Yes

Keywords

CD8 T cell
adeno-associated virus
dendritic cell
innate immunity
type I interferon

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ymthe.2019.11.011

Cite this

@article{8ae52b8ae04448e7a9055b98d76bb28d,

title = "Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells",

abstract = "Immune responses complicate the use of adeno-associated virus (AAV) vectors in human gene therapy. Shirley et al. define a mechanism by which cross-presentation of viral capsid results in activation of CD8+ T cells, which involves sensing of IFN I by conventional dendritic cells and co-stimulation by CD4+ T helper cells.",

keywords = "CD8 T cell, adeno-associated virus, dendritic cell, innate immunity, type I interferon",

author = "Shirley, \{Jamie L.\} and Keeler, \{Geoffrey D.\} and Alexandra Sherman and Irene Zolotukhin and Markusic, \{David M.\} and Hoffman, \{Brad E.\} and Morel, \{Laurence M.\} and Wallet, \{Mark A.\} and Cox Terhorst and Herzog, \{Roland W.\}",

note = "Publisher Copyright: {\textcopyright} 2019 The American Society of Gene and Cell Therapy",

year = "2020",

month = mar,

day = "4",

doi = "10.1016/j.ymthe.2019.11.011",

language = "English (US)",

volume = "28",

pages = "758--770",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells

AU - Shirley, Jamie L.

AU - Keeler, Geoffrey D.

AU - Sherman, Alexandra

AU - Zolotukhin, Irene

AU - Markusic, David M.

AU - Hoffman, Brad E.

AU - Morel, Laurence M.

AU - Wallet, Mark A.

AU - Terhorst, Cox

AU - Herzog, Roland W.

PY - 2020/3/4

Y1 - 2020/3/4

N2 - Immune responses complicate the use of adeno-associated virus (AAV) vectors in human gene therapy. Shirley et al. define a mechanism by which cross-presentation of viral capsid results in activation of CD8+ T cells, which involves sensing of IFN I by conventional dendritic cells and co-stimulation by CD4+ T helper cells.

AB - Immune responses complicate the use of adeno-associated virus (AAV) vectors in human gene therapy. Shirley et al. define a mechanism by which cross-presentation of viral capsid results in activation of CD8+ T cells, which involves sensing of IFN I by conventional dendritic cells and co-stimulation by CD4+ T helper cells.

KW - CD8 T cell

KW - adeno-associated virus

KW - dendritic cell

KW - innate immunity

KW - type I interferon

UR - https://www.scopus.com/pages/publications/85075874491

UR - https://www.scopus.com/pages/publications/85075874491#tab=citedBy

U2 - 10.1016/j.ymthe.2019.11.011

DO - 10.1016/j.ymthe.2019.11.011

M3 - Article

C2 - 31780366

AN - SCOPUS:85075874491

SN - 1525-0016

VL - 28

SP - 758

EP - 770

JO - Molecular Therapy

JF - Molecular Therapy

IS - 3

ER -